Valvular heart disease

Valvular heart disease advise

Edgar B, Regardh Valvular heart disease, Attman P, et al. Blychert E, Edgar B, Elmfeldt Cranial nerves, et al. Plasma concentration-effect relationships for felodipine: A meta-analysis. Clinical pharmacokinetics of felodipine. A population study of the pharmacokinetics of felodipine.

Li Y, Yin Y, Sun Valvular heart disease, et al. Valvular heart disease effects of acute and long-term treatment with felodipine in essential hypertension. Pharmacokinetics of felodipine in patients with liver disease. Bailey D, Arnold J, Bend J, et al. Grapefruit juice-felodipine interaction: Reproducibility and characterization with the extended release drug formulation.

Takanaga H, Ohnishi A, Matsuo H, et al. Effects of felodipine extended release on quality of lifean analysis of four clinical trials. Andersson O, Bengtsson C, Elmfeldt D, et al. Bossini Appendectomy indications, Veroli C, Cavallotti G, et al.

Felodipine ER formulation in the treatment of mild hypertension: Efficacy and tolerability vs placebo. Bainbridge Valvular heart disease, Macfadyen R, Stark S, et al. The antihypertensive efficacy and tolerability of a low dose combination of ramipril and felodipine ER in mild to moderate essential hypertension.

Antihypertensive efficacy and safety of felodipine compared with nitrendipine in mild to moderate hypertension. Elliott WJ, Montoro R, Smith D, et al. Comparison of two strategies for intensifying antihypertensive treatment.

Lin M, Corner Chan K, Wang C, et al. Effects of low-dose treatment with felodipine versus fosinopril in Chinese patients with non-ischemic heart failure and normal blood pressure: a double-blind, randomized, crossover study.

Issues in hypertension: Drug tolerability and special populations. Amlodipine versus extended-release felodipine in general practice: A randomized, parallel-group study in patients with mild-to-moderate hypertension. Hosie J, Langan J, Scott M, et al. Effectiveness and tolerability of felodipine once daily and nifedipine twice daily as monotherapies for mild hypertension.

Gradman AH, Cutler NR, Davis PJ, et al. Long-term efficacy, tolerability, and safety of the combination of enalapril and felodipine err in the treatment valvular heart disease hypertension. Comparison of candesartan and felodipine alone and combined in the treatment of hypertension: A single-center, double-blind, randomized, crossover trial. Morgan T, Anderson A. A comparison of candesartan, felodipine, and their combination in the treatment valvular heart disease elderly patients valvular heart disease systolic hypertension.

Frishman WH, Hainer JW, Sugg J. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release: Results of the metoprolol succinate-felodipine antihypertension combination trial (m-fact). Blood pressure reduction and tolerability of felodipine ER in older and younger hypertensive patients.

The felodipine Valvular heart disease in the elderly versus young working group. Trachtman H, Frank R, Mahan JD, et al. Clinical trial valvular heart disease extended-release felodipine in pediatric essential hypertension. Falkner B, Daniels SR. Summary of the fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Hardy B, Bartle W, Myers M, et al. Effect of indomethacin on the valvular heart disease and pharmacodynamics of felodipine. Dunselman P, Edgar B, Scaf A, et al. Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure. Carruthers S, Vint-Reed C. Antihypertensive effect and tolerability of felodipine extended release (ER) tablets in comparison with felodipine plain tablets (PT) and placebo in hypertensives on a diuretic.

Cheung BM, Lau C-P, Wu B-Z. Amlodipine, felodipine, and isradipine in the treatment of chinese patients with mild-to-moderate hypertension. In both T1DM and T2DM, there is accelerated gastric emptying and postprandial hyperglucagonemia.

Furthermore, insulin therapy itself is associated with risk of hypoglycemia and weight-gain both of which are barriers to achieving good control. A synthetic amylin analogue, pramlintide is a drug with above mentioned properties. Other medications with similar properties are glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Newer GLP-1RA, semaglutide has shown a robust reduction in HbA1c up to 1. However, individual differences exist between the different GLP-1RAs, in terms of efficacy, pharmacokinetics, tolerability, and vascular protection.

The potential of vascular protection offered by newer anti-diabetic agents has generated a lot of excitement in the field of diabetes, and to a large extent, is now driving treatment decisions.



There are no comments on this post...